Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Target Price of $12.67

Key Points

• Analysts have a consensus “Hold” rating on Verrica Pharmaceuticals, with three buys, one hold, and one sell among five firms. The average 12-month price target is $12.67.
• Armistice Capital increased its stake by 75.1% to 1.12 million shares, representing 7% of Verrica; institutional investors collectively own 42.45% of the company.
• VRCA opened at $4.18, compared with a 52-week range of $3.28 to $9.82. Verrica is developing dermatology treatments, including FDA-approved YCANTHE for molluscum contagiosum.

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) have earned a consensus rating of "Hold" from the five research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $12.67.

VRCA has been the topic of several recent research reports. Wall Street Zen upgraded Verrica Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, September 26th. Lake Street Capital began coverage on Verrica Pharmaceuticals in a research report on Thursday, August 27th. They issued a "buy" rating and a $9.00 price objective for the company. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Armistice Capital LLC increased its stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) by 75.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,118,925 shares of the company's stock after buying an additional 479,732 shares during the period. Armistice Capital LLC owned 7.00% of Verrica Pharmaceuticals worth $9,298,000 at the end of the most recent reporting period. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Price Performance

VRCA stock opened at $4.18 on Friday. The firm has a market cap of $71.81 million, a P/E ratio of -2.50 and a beta of 1.60. The firm's fifty day moving average is $4.88 and its 200 day moving average is $5.60. Verrica Pharmaceuticals has a 52 week low of $3.28 and a 52 week high of $9.82. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases with limited or inadequate therapeutic options. The company's work centers on topical therapies designed for use in dermatology practices and other healthcare settings.

Verrica's lead product, YCANTHE (cantharidin), is a topical solution approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children two years of age and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.